These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36123046)

  • 1. Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men.
    Kunimura A; Miura K; Segawa H; Torii S; Kondo K; Hisamatsu T; Kadota A; Fujiyoshi A; Yano Y; Nakagawa Y; Okamura T; Ueshima H
    J Atheroscler Thromb; 2023 Jul; 30(7):767-777. PubMed ID: 36123046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.
    Kunimura A; Yano Y; Hisamatsu T; Torii S; Kondo K; Kadota A; Fujiyoshi A; Okamura T; Watanabe Y; Shiino A; Nozaki K; Ueshima H; Miura K;
    Eur J Neurol; 2023 May; 30(5):1327-1334. PubMed ID: 36727585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Jin JL; Sun D; Guo YL; Wu NQ; Zhu CG; Xu RX; Sun J; Santos RD; Li JJ
    Eur J Prev Cardiol; 2021 Apr; 28(3):272-279. PubMed ID: 33891693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Furin-Cleaved Proprotein Convertase Subtilisin/Kexin Type 9 Concentration Predicts Future Coronary Events in Japanese Subjects.
    Kataoka Y; Harada-Shiba M; Hori M; Watanabe M; Kokubo Y; Noguchi T; Yasuda S; Miyamoto Y
    JACC Asia; 2021 Dec; 1(3):360-368. PubMed ID: 36341208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between proprotein convertase subtilisin/kexin type 9 and late saphenous vein graft disease after coronary artery bypass grafting: a cross-sectional study.
    Gao J; Wang HB; Xiao JY; Ren M; Reilly KH; Li YM; Liu Y
    BMJ Open; 2018 Jul; 8(7):e021951. PubMed ID: 29991632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
    Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
    Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
    Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
    J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin kexin type 9 and main artery atherosclerosis in patients with arterial hypertension.
    Vukolova Y; Gubareva I; Galati G; Germanova O
    Minerva Cardiol Angiol; 2023 Apr; 71(2):129-134. PubMed ID: 35420281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease.
    Rasmussen LD; Bøttcher M; Ivarsen P; Jørgensen HS; Nyegaard M; Buttenschøn H; Gustafsen C; Glerup S; Bøtker HE; Svensson M; Winther S
    Nephrol Dial Transplant; 2020 Apr; 35(4):632-639. PubMed ID: 30137516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
    Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
    J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
    Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D
    Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
    Werner C; Hoffmann MM; Winkler K; Böhm M; Laufs U
    Vascul Pharmacol; 2014 Aug; 62(2):94-102. PubMed ID: 24685817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
    Leander K; Mälarstig A; Van't Hooft FM; Hyde C; Hellénius ML; Troutt JS; Konrad RJ; Öhrvik J; Hamsten A; de Faire U
    Circulation; 2016 Mar; 133(13):1230-9. PubMed ID: 26896437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.